Nov 15 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.17 USD | -4.44% | -11.47% | +37.50% |
09/05 | Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.50% | 284M | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
+20.84% | 2.42B | |
-26.13% | 2.32B | |
+19.31% | 2.17B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- U.S. FDA approves CorMedix's antimicrobial drug